Eli Lilly and Co LLY on Thursday agreed to acquire AtaiBeckley Inc. ATAI in a deal that values the clinical-stage mental ...
Canada's Drug Agency recognizes the clinical value of LEQEMBI®in slowing Alzheimer's progression and helping keep patients in ...
The Department of Veterans Affairs is asking veterans and others to weigh in on proposed changes to two lengthy applications.
New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target ...
Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and other strategic ...
Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with ...
SDA has awarded $1.75 billion in AMDT3 OTA agreements to L3Harris and Sierra Space for 36 missile warning and missile defense ...
The Army is accepting applications for a highly competitive, three-year broadening opportunity aimed at connecting tactical ...
The world’s largest independent production group has been created. Its next challenge is finding growth beyond the ...
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, ...
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results